Clinical Insights

FDA Approves Klygefa (Gefurulimab) for AChR Antibody Positive Generalized Myasthenia Gravis

FDA Approves Klygefa (Gefurulimab) for AChR Antibody Positive Generalized Myasthenia Gravis

The US Food and Drug Administration (FDA) has approved Klygefa (gefurulimab) for the treatment of generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody positive. gMG is a chronic autoimmune neuromuscular disease...

Sanofi’s Orphan Drug Supply Update | The CheckRare Brief Special Edition

Sanofi’s Orphan Drug Supply Update | The CheckRare Brief Special Edition

On this special edition of the CheckRare Brief, we talk with Alaa Hamed, Sanofi’s Global Head of Medical Affairs for Rare Diseases, and Maite Durrenbach, Head of Specialty Care Manufacturing and Supply at Sanofi, about the company’s current supply chain problems for some of their biological therapies.

More

Highlights from The Liver Meeting 2026 | The CheckRare Brief

In this episode, we discuss highlights from The Liver Meeting, Ultragenyx program cuts, and ANI Pharmaceuticals’ offer to buy Egetis Therapeutics.     Ultragenyx Ends Angelman Syndrome and...

3D Printed Treatment Options | The CheckRare Brief

In this episode, we discuss a new formulation of treatment for HAE, the FDA approval of Voceryq for recurrent respiratory papillomatosis, and 3D printed treatment options.       New...

Plasminogen Deficiency: Fibrin Accumulation and Its Effects on Patients

Plasminogen Deficiency: Fibrin Accumulation and Its Effects on Patients

Plasminogen deficiency is caused by variants in the PLG gene and is characterized by the appearance of ligneous fibrin on mucous membranes.

Recent Videos

Social Wall

Trutakna Meets All Prespecified Endpoints in Phase 3 ORIGIN 3 Trial in IgA Nephropathy

Trutakna Meets All Prespecified Endpoints in Phase 3 ORIGIN 3 Trial in IgA Nephropathy

The Need for Earlier Pulmonary Hypertension Screening in Interstitial Lung Disease

New research is helping advance the understanding and treatment of rare kidney diseases.

The VALIANT study evaluated pegcetacoplan, a targeted complement therapy, in patients with C3G and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN).

Explore the

The Need for Earlier Pulmonary Hypertension Screening in Interstitial Lung Disease

What should you know about myasthenia gravis?

From understanding the underlying disease mechanisms to exploring FDA-approved treatment options and ongoing clinical research, staying informed is essential for the rare disease community.

The Myasthenia Gravis Disease Learning